AstraZeneca (NYSE:AZN) Share Price Crosses Above 200 Day Moving Average - Time to Sell?

Key Points

• AstraZeneca shares rose above their 200-day moving average, trading as high as $188.39 and last changing hands at $186.49, signaling improved technical momentum.
• The company reported a strong third quarter, with EPS of $2.79 and revenue of $16.21 billion exceeding expectations. Oncology sales grew 17%, while management reaffirmed its 2026 guidance and cited more than $20 billion in potential from 2027 trial readouts.
• Analyst sentiment is broadly positive, with a consensus “Moderate Buy” rating and $206.67 target price, though generic competition affecting mature products such as Farxiga and some valuation concerns remain risks.

AstraZeneca Plc (NYSE:AZN - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $180.21 and traded as high as $188.39. AstraZeneca shares last traded at $186.49, with a volume of 5,464,384 shares traded.

Key Headlines Impacting AstraZeneca

Here are the key news stories impacting AstraZeneca this week:

• Positive Sentiment: Q3 earnings beat expectations: Core EPS reached $2.79 versus the roughly $2.60 analyst consensus, while revenue increased about 7% year over year to $16.21 billion, topping estimates near $16 billion. Net profit rose to $3.12 billion from $2.54 billion a year earlier. AstraZeneca Stock Rallies on Q3 Earnings Beat
• Positive Sentiment: Oncology remains the key growth engine: Cancer-drug sales rose 17%, helping offset generic competition and declining sales from mature medicines such as Farxiga. The performance suggests AstraZeneca’s newer products are mitigating patent-cliff pressure. AZN Q3 Earnings Beat Estimates
• Positive Sentiment: Pipeline catalysts support the longer-term story: Management highlighted more than $20 billion of potential from 2027 drug-trial readouts, while the company reported 12 positive Phase 3 readouts. These catalysts could expand AstraZeneca’s growth prospects beyond its current portfolio. AstraZeneca CEO Sees Over $20B Potential
• Positive Sentiment: Guidance was reaffirmed: AstraZeneca maintained its fiscal 2026 outlook for mid-to-high single-digit revenue growth and low-double-digit core EPS growth at constant exchange rates. The company also targeted $1.5 billion in annual savings, potentially supporting margins and earnings. AstraZeneca Reports Q3 Revenue Growth
• Neutral Sentiment: Analyst views remain mixed: Guggenheim maintained a Buy rating, while Deutsche Bank retained Hold and Erste Group Bank lowered its FY2026 EPS estimate, indicating some valuation and execution concerns remain. Guggenheim Maintains Buy Rating
• Negative Sentiment: Generic competition remains a headwind: Farxiga and other mature products face pricing and volume pressure, which could limit growth if newer oncology and pipeline medicines do not continue to scale. AstraZeneca Holds Guidance

Analysts Set New Price Targets

Several research firms have recently issued reports on AZN. Nordea Equity Research raised shares of AstraZeneca from a "sell" rating to a "buy" rating in a research note on Tuesday, October 13th. Citigroup restated a "buy" rating on shares of AstraZeneca in a report on Tuesday, October 6th. Weiss Ratings raised AstraZeneca from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Monday. HSBC lowered AstraZeneca from a "buy" rating to a "hold" rating in a research report on Monday, July 13th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a "sell" rating to a "hold" rating in a research report on Tuesday, September 15th. Sixteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $206.67.

AstraZeneca Stock Performance

The company's 50 day moving average price is $164.48 and its 200-day moving average price is $180.21. The stock has a market cap of $289.23 billion, a P/E ratio of 27.88, a price-to-earnings-growth ratio of 1.35 and a beta of 0.27. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.67 and a current ratio of 0.89.

AstraZeneca (NYSE:AZN - Get Free Report) last released its earnings results on Friday, October 30th. The company reported $2.79 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.60 by $0.19. AstraZeneca had a return on equity of 31.45% and a net margin of 17.02%. The business had revenue of $16.21 billion during the quarter, compared to the consensus estimate of $16 billion. During the same period last year, the business posted $2.38 earnings per share. The business's revenue for the quarter was up 6.5% on a year-over-year basis. Equities analysts forecast that AstraZeneca Plc will post 10.21 EPS for the current fiscal year.

Institutional Trading of AstraZeneca

Hedge funds and other institutional investors have recently bought and sold shares of the company. Mascoma Wealth Management LLC bought a new position in AstraZeneca during the first quarter valued at approximately $26,000. Roxbury Financial LLC bought a new stake in AstraZeneca in the 2nd quarter worth approximately $29,000. Resources Management Corp CT ADV bought a new stake in AstraZeneca in the 1st quarter worth approximately $35,000. Allied Private Wealth LLC bought a new stake in AstraZeneca in the 2nd quarter worth approximately $35,000. Finally, Laurel Wealth Advisors LLC purchased a new stake in shares of AstraZeneca during the 3rd quarter worth approximately $30,000. Institutional investors own 20.35% of the company's stock.

AstraZeneca Company Profile

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.

AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.